Although lapatinib has shown activity against HER2 positive breast cancer that has metastasised to brain, we designed to exclude patients given the concern over rapid progression of patients with brain metastasis and the heterogeneous patient population that could potentially affect our clinical outcome analysis. Here, ERBB2 is linked to breast cancer.